The cells glow green under the high-powered microscope, each bedazzled with a constellation of luminous proteins and RNA that, like oil droplets in water, have huddled together through a process known ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology ...

WILMINGTON, DE — NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study evaluating NKT5097, an oral small molecule designed to ...

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year ...

Approach that uses cell’s own strategy of liquid-liquid phase separation protects synthetic modifications from being washed away by the tide of cell growth.

Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of two abstracts for poster presentations at ...

Discover Kymera Therapeutics' Q3 2025 earnings, clinical trial milestones in immunology, and strategic Gilead partnership.

Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium Avenzo Therapeutics, Inc. ( ...